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Fever in neutropenia (FN) is the most frequent potentially lethal complication of chemotherapy in 
patients with cancer. The temperature limit defining fever (TLDF) for FN is based on scarce evidence. 
this prospective, single center observational study recruited non-selected pediatric patients diagnosed 
with cancer between ≥1 and ≤17 years in 2012 and 2013. Of 40 patients potentially eligible, 39 
participated. Data of 8896 temperature measurements and 1873 complete blood counts (CBCs) 
were recorded over 289 months (24.1 years) of chemotherapy exposure time. During this time 43 FN 
episodes were diagnosed. In 32 episodes, FN diagnosis was based on reaching the local (i.e. Bern, 
Switzerland) standard TLDF of 39.0 °C; another 11 episodes had been captured by clinical judgement 
(i.e. temperature < 39.0 °C). These data can be used to simulate the effects of various TLDFs on the rate 
of FN diagnosis. We assume merging these data with other data sets is feasible.
Background & Summary
Fever in chemotherapy-induced neutropenia (FN) is the most frequent potentially lethal complication of 
chemotherapy in pediatric and adult patients with cancer and should be managed as a medical emergency. 
Severe neutropenia is usually defined and applied in pediatric oncology practice as an absolute neutrophil count 
(ANC) ≤ 0.5 G/L, or ≤1.0 G/L and expected to rapidly decline1,2.
To reduce the risk of developing FN during chemotherapy, several prophylactic strategies have been used, 
such as isolation of the patient, antibiotic administration, and administration of granulocyte stimulating growth 
factors3. The current standard therapy for FN implies emergency hospitalization, empirical administration of 
intravenous broad-spectrum antimicrobial therapy, and antipyretics, with or without escalation to include anti-
fungal therapy1,4–6.
Surprisingly, the temperature limit defining fever (TLDF), which directly influences the definition and diagno-
sis and thus the incidence of FN, varies considerably between different pediatric oncology centers1,5. This reflects 
the fact that an internationally accepted evidence-based TLDF definition is still missing in pediatric oncology7, 
and has been declared to be a research gap in recent pediatric FN guidelines4. This TLDF has direct implica-
tions on individual patient management, health-related quality of life, resource utilization, cost, and potentially 
treatment-related mortality8. Of course, efficacy – avoiding non-necessary FN diagnoses - must be weighed 
against safety – avoiding delays in FN diagnosis and thus empirical antibiotic therapy- for the determination of 
a clinically used TLDF.
The data described here9 had been collected during a prospective observational study (August 11, 2012 to May 
31, 2013) in pediatric patients diagnosed with cancer between ≥1 to ≤17 years and treated with chemotherapy 
in a single center (Bern, Switzerland) applying a standard TLDF of 39.0 °C ear temperature (NCT01683370). The 
treating physician was free to diagnose FN below this TLDF if clinically indicated. The study was powered to 
determine the rate of FN episodes additionally diagnosed by lower versus standard TLDFs. Analytical results on 
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the influence of virtually applying different lower TLDFs on FN diagnosis have been published8. We publish these 
data so they can be merged with other data, with the specific aim to generate evidence upon which the choice of 
a TLDF for FN diagnosis can be based. It is important to note that during the NCT01683370 study, temperature 
measurements after FN diagnosis, i.e., during FN, were collected too. To reflect this different clinical situation, the 
respective analytical results have been published separately10, and those data will be described separately as well.
In total, 39 of 40 potentially eligible patients participated in this study, while the parents of one patient denied 
informed consent. During 8799 days (289 months, 24.1 years) of chemotherapy exposure time (CET) (median 
CET, 199 days per patient; range, 63 to 366), 8896 temperature measurements were recorded (median rate, 26 
measurements per patient per month; IQR, 8 to 53; range, 0 to 237). The median temperature measured was 
37.1 °C (IQR, 36.7 to 37.6; range, 35.0 to 41.2), and 283 (3.2%) temperatures were ≥39.0 °C. In total, 43 FN epi-
sodes were diagnosed in 20 of the 39 patients. Of these, 32 FN episodes were diagnosed at temperatures ≥39.0 °C. 
11 FN episodes, all with an ANC ≤ 0.5 G/L, were diagnosed at temperatures below the standard TLDF of 39.0 °C 
(range, 38.0 °C to 38.9 °C) for different clinical reasons. Twice, FN was not diagnosed and the patients were not 
hospitalized despite fever ≥39.0 °C during neutropenia. Both patients were in acute lymphoblastic leukemia 
maintenance therapy, had been diagnosed with an upper airway infection with good general condition within 
24 hours before fulfilling FN criteria, later received oral antibiotics, with uneventful clinical course.
During the study period, 1873 CBCs were recorded (median rate of 6 CBCs per patient per month; IQR, 4 
to 8; range, 2 to 23). The ANC was ≤0.5 G/L in 435 CBCs (23%). In 244 CBCs (13%), it was in-between 0.5 and 
1.0 G/L. In 1032 CBCs the ANC reached >1.0 G/L and in 162 (9%) it was unknown8.
These data can be used to simulate the effects of various TLDFs on the rate of FN diagnosis. We assume merg-
ing these data with other data sets is feasible.
There is a data overlap of nearly 5 months (August 11, 2012, to December 31, 2012) with two separate data 
descriptors, both reporting on retrospectively collected patients under chemotherapy at risk to develop FN11, and 
on the corresponding FN episodes12 from January 1, 1993 to December 31, 2012. Temperature measurements 
and serial CBCs, except for those leading to FN diagnosis, are not included into the data of these two datasets.
Methods
These methods are expanded versions of descriptions in our related work8.
study design. The data described here9 had been collected during the study “Pediatric FN Definition 2012 
Bern”. This prospective, single-center observational study was open for recruitment from August 11, 2012 to May 
31, 2013 at the Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University 
Hospital, University of Bern, Switzerland. This hospital provides tertiary care for a population of roughly one 
million inhabitants. The Division of Pediatric Hematology/Oncology unit has an inpatient unit with 8 beds, plus 
a large outpatient unit. It treats around 40 newly diagnosed pediatric patients with all kind of malignancies per 
year. Besides, it performs myeloablative chemotherapy followed by autologous stem cell transplantation for the 
majority of Switzerland, covering around 6 million inhabitants.
Patient recruitment was closed on May 2013, and follow-up was closed on August 07, 2013, when the prede-
termined accrual goal of 32 FN episodes with fever ≥39 °C was reached. Participation in this observational study 
did not influence any diagnostic nor therapeutic decisions.
The study was conducted in accordance with the Declaration of Helsinki13. Before starting patient accrual, 
the protocol was approved by the Institutional Review Board (Ethikkommission der Universitätskinderkliniken 
Bern) and registered at www.clinicaltrials.com (NCT01683370). Analytical results of these data and of data stud-
ied after FN diagnosis have been published elsewhere8,10.
The data described here were not published together with the analytical results, in PLOS One, because they 
had to be fully anonymized before publication in order to comply with the current Swiss research legislation. The 
anonymization process was performed in 2018 to enable data sharing.
Patients. To enter the study, the patients had to fulfill all inclusion criteria: age ≥1 year and ≤17 years at time 
of recruitment, chemotherapy treatment for ≥2 months because of a malignancy at time of recruitment, and 
written informed consent from patients and/or their parents. Infants younger than one year and patients without 
written informed consent were excluded.
Patients were excluded when informed consent was withdrawn, and when chemotherapy was completed, 
i.e., 2 weeks after the last dose of chemotherapy or date of ANC recovery >0.5 G/L, whichever came later. Of 
40 potentially eligible patients, 39 participated in the study, while the parents of one patient denied informed 
consent.
Clinical management. Patients were treated with chemotherapy, including myeloablative therapy followed 
by autologous peripheral blood stem cell transplantation, or multimodal therapy, according to internationally 
established protocols.
In inpatients, ear temperature was measured routinely twice a day. Additional measurements were made when 
fever was suspected, as well as before and during transfusions and medications known to potentially induce fever. 
In outpatients, parents were instructed to measure ear temperature when they suspected fever and to note the 
results on paper forms.
CBCs were routinely performed once or twice a week according to disease. Additional CBCs were performed 
if temperature was ≥39.0 °C, in case of reduced general condition or other problems. Patients with fever with-
out severe neutropenia (ANC > 0.5 G/L) and in good general condition were allowed to take oral paracetamol. 
Patients with fever and severe neutropenia (ANC ≤ 0.5 G/L) or in reduced general condition were seen in the 
emergency department and usually diagnosed with FN, implying emergency hospitalization and empirical 
3Scientific Data |           (2019) 6:108  | https://doi.org/10.1038/s41597-019-0112-8
www.nature.com/scientificdatawww.nature.com/scientificdata/
therapy with intravenous broad-spectrum antibiotics, usually ceftriaxone plus amikacin and antipyretics. Thus, 
the management of FN was similar to the current standard therapy described above1,3,4,6.
Fever in neutropenia. During this study, FN was diagnosed when a patient had chemotherapy-induced 
severe neutropenia and fever (single ear temperature ≥39.0 °C) or the physician in charge decided to start empir-
ical antimicrobial treatment based on her/his clinical judgement. With increasing or plateau temperature, this 
TLDF corresponds to 39.1 °C core temperature, and to 38.4 °C axillary temperature14.
Neutropenia was defined as a peripheral blood ANC ≤ 0.5 G/L, or ≤1 G/L and expected to decline, induced by 
chemotherapy, i.e. ≥7 days after first start of chemotherapy, irrespective of the setting.
The start of FN corresponded to the time of hospitalization and start of empirical antimicrobial therapy for 
FN, as clinically decided by the treating physician. Patients were usually discharged if they were afebrile for 
≥48 hours and clinically well, initial blood cultures were negative, and leukocyte counts and/or ANC were rising 
(irrespective of their absolute value)8. The FN episode ended with the end of any antimicrobial therapy for FN. 
Restarting antimicrobial therapy within 7 days and with persistent neutropenia was considered to belong to the 
same FN episode8.
Data coverage of this study. This study collected data on temperature measurements and CBCs before 
and after the FN episode.
Data on temperature measurements and CBCs performed during the FN episode are published elsewhere10 
and are not part of the data described here. Data collected at FN diagnosis and at the end of the FN episode are 
published in both datasets.
Data Records
A single data record resulted from this study (Table 1). It contains 39 data files, one per patient (File Pediatric_
FN_Definition_2012.Patient_xxxx.csv.), where xxxx refers to a patient-specific random four digit number 
between 1000 and 9999, plus a key file (Pediatric_FN_Definition_2012.Key.csv). Data are available within the 
figshare repository9.
technical Validation
Data collection. An experienced pediatric oncology nurse extracted information from the paper forms 
brought in by parents as described above and from patient charts within the setting of a prospective clinical study. 
This information was checked for plausibility and, if not plausible, for agreement with charts by a pediatric oncol-
ogist (RAA) before analysis8. The data was then entered into a spreadsheet.
Reduction of recruitment bias. 39 of 40 potentially eligible patients participated in the study and there-
fore, a relevant recruitment bias can be excluded. Correspondingly, the distribution of gender (23 males and 
16 females), age at diagnosis (median, 7.4 years; range, 1.2 to 16.7) and diagnostic groups (acute lymphoblastic 
leukemia in 18 patients, acute myeloid leukemia in 2, Non-Hodgkin lymphoma in 2, central nervous system 
tumor in 5, and other solid tumors in 12) were comparable with an unselected population of pediatric patients 
with cancer8.
increasing reliability of information. A simple restricted definition of FN episodes based on verifia-
ble quantitative information both on fever and on neutropenia was used in the vast majority of FN diagno-
ses. Additional FN episodes could be diagnosed by the treating physician before the standard TLDF if clinically 
indicated8.
Temperature was always measured in the ear by infrared tympanic thermometry using the same device, a 
Braun ThermoScan 5 (IRT 4520; Braun GmbH, Kronberg, Germany; steps displayed, 0.1 °C; accuracy, ±0.2 °C; 
clinical repeatability, ±0.14 °C), during hospitalization, in the outpatient clinics, and at home.
During febrile and non-febrile periods in children, infrared tympanic thermometry measurements more 
accurately reflect core temperatures than any other measurement site14.
anonymization process. Data were irreversibly anonymized before publication in order to comply with 
the current Swiss research legislation. First, a four digit random number, not linkable to the patient number used 
in the initial study, was used per patient. Second, diagnoses, age and gender, which are all classified as indirect 
identifiers are not apparent in the published dataset. Third, the date of study start, classified as direct identifier15,16, 
was always replaced by day 0, to prevent identification. Further dates were replaced by numbers indicating the 
time distance (in days) from day 0. The real time of the day is expressed as fraction of the day. Fourth, CBCs might 
be considered as identifying numbers15,16, because of the almost uniquely occurring data combination of hemo-
globin, leukocytes, platelets and ANC. Different anonymization techniques, such as data aggregation, rounding, 
swapping data or adding noise had been discussed17,18. Weighing advantages and disadvantages we finally decided 
to use no anonymization method and to publish original data, in order not to hamper the future analysis of these 
published data.
Observations Time covered Center Data source Data
Patients 08.2012–08.2013 Bern Chart records Pediatric_FN_Definition_2012.Patient_xxxx.csv
Table 1. Overview.
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Code availability
This study did not use any computer codes to generate the dataset. Microsoft Excel was used to enter, store and 
quality check the collected data.
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